Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals,
…
Articles by : Laura Gilcrest, Contributor
A New York state lawmaker and strong 340B program supporter last week introduced bills to help 340B providers hurt by the state’s transfer of Medicaid managed care drug benefits to Medicaid fee for service on April 1.
Under Medicaid managed
…
Drug manufacturer Janssen Pharmaceuticals said last week it would pay refunds for overcharges on 340B drugs purchased in the second quarter of 2020, including top-selling psoriasis drug Stelara.
Janssen, part of Johnson & Johnson, said it owes or may owe
…
Generic drug manufacturers Lifestar Pharma and Chartwell Pharmaceuticals may owe refunds to 340B covered entities for overcharges on drugs purchased from the companies in the fourth quarter of 2022, according to recent notices posted on the U.S. Health Resources and
…
Former Republican Congressman Dan Burton (Ind.) called the 340B program “a win for all parties involved” in a Kokomo, Indiana newspaper op-ed this week and said a current House Republican’s 340B bill could deny vulnerable Hoosiers access to care.
Rep.
…
Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use
…
The 340B program has evolved into a “buy low, sell high” drug pricing system abused by some hospitals that have profits as their main goal, a health policy researcher told lawmakers Wednesday at a U.S. House subcommittee hearing.
The House
…
The Iowa Senate last week passed a House-approved bill banning pharmacy benefit manager and payor discrimination against 340B covered entities and their contract pharmacies, including reimbursing the entities at a lower rate than non-340B providers.
The Senate voted 49-1 on
…
Three groups representing 340B hospitals late last week filed an amicus brief in federal circuit court in support of Arkansas’ novel contract pharmacy law, arguing the law doesn’t conflict with the 340B statute and in fact furthers the goals of
…